Advertisement

Collaboration › Details
BioNTech–JPMorgan Chase: investor conference, 202301 supply service BioNTech presents at JP Morgan Healthcare Conference 2023
![]() |
Period | 2023-01-10 |
![]() |
Region | San Francisco, CA |
Country | United States (USA) | |
![]() |
Partner, 1st | BioNTech SE (Nasdaq: BNTX) |
Group | BioNTech (Group) | |
Partner, 2nd | J.P. Morgan Securities LLC | |
Group | JPMorgan Chase (Group) | |
![]() |
Product | J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco |
Product 2 | mRNA technology | |
![]() |
Person | Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH) |
Person 2 | Maas, Sylke (BioNTech 202005 VP Investor Relations + Business Strategy) | |
BioNTech SE. (12/28/22). "Press Release: BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference". Mainz.
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.
A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.com/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit www.BioNTech.com.
CONTACT
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Record changed: 2023-01-05 |
Advertisement

More documents for BioNTech (Group)
- [1] BioNTech SE. (1/10/23). "Press Release: BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development". Mainz & London....
- [2] BioNTech SE. (12/28/22). "Press Release: BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference". Mainz....
- [3] BioNTech SE. (9/1/22). "Press Release: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union". New York, NY & Mainz....
- [4] BioNTech SE. (8/31/22). "Press Release: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older". New York, NY & Mainz....
- [5] BioNTech SE. (8/22/22). "Press Release: Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine". New York, NY & Mainz....
- [6] BioNTech SE. (8/8/22). "Press Release: BioNTech Announces Second Quarter Financial Results and Corporate Update". Mainz....
- [7] BioNTech SE. (8/5/22). "Press Release: BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates". Mainz & Copenhagen....
- [8] CureVac N.V.. (7/5/22). "Press Release: CureVac Files Patent Infringement Lawsuit in Germany against BioNTech". Tübingen & Boston, MA....
- [9] BioNTech SE. (4/11/22). "Press Release: BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines". Mainz & Beminster, NJ....
- [10] BioNTech SE. (3/8/22). "Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo (cemiplimab) Combination in NSCLC". Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top